Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2026)

Amylyx Pharmaceuticals' Change in Account Payables history runs 6 years deep, the most recent figure standing at $10000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables fell 99.47% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at -$1.3 million (up 92.27% YoY), while the FY2025 annual figure was $580000.0, up 103.04% from the prior year.
• Change in Account Payables was $10000.0 for Q1 2026 at Amylyx Pharmaceuticals, down from $275000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $15.8 million in Q4 2023 to a low of -$18.4 million in Q3 2023.
• Historically, Change in Account Payables has averaged -$45647.1 across 5 years, with a median of -$33000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables soared 2736.16% in 2022, then tumbled 1570.57% in 2023.
• A 5-year view of Change in Account Payables shows it stood at -$800000.0 in 2022, then surged by 2077.5% to $15.8 million in 2023, then tumbled by 90.7% to $1.5 million in 2024, then tumbled by 81.32% to $275000.0 in 2025, then tumbled by 96.36% to $10000.0 in 2026.
• The last three Change in Account Payables figures came in at $10000.0 (Q1 2026), $275000.0 (Q4 2025), and -$33000.0 (Q3 2025), per Business Quant data.